Docetaxel (Taxotere) in combination with platinums in patients with non-small cell lung cancer: Trial data and implications for clinical management

Seminars in Oncology

Volumn 28, Issue 1 SUPPL. 2, 2001, Pages 10-14

  Belani, Chandra ^a,c   Lynch, Thomas ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PLATINUM DERIVATIVE;

ANEMIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

EID: 0035080016     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.18403     Document Type: Review

References (35)

1. Principals of cancer management: Chemotherapy
2. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
3. Phase I/II study of cisplatin and docetaxel in non-small cell lung cancer
4. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small cell lung cancer
5. Phase I/II study of docetaxel and cisplatin in patients with previously untreated metastatic non-small cell lung cancer
6. Docetaxel (Taxotere) plus cisplatin: An active alternative and well tolerated combination in patients with advanced non-small cell lung cancer
7. Phase II study of docetaxel and cisplatin in advanced non-small cell lung cancer
8. Multicenter phase II study of docetaxel and cisplatin combination in patients with non-small cell lung cancer
9. Phase II study of docetaxel plus cisplatin in a circadian timing as first line chemotherapy in advanced non small cell lung cancer
10. Defining the dose of docetaxel (Taxotere) in combination chemotherapy of non-small cell lung cancer: Preserving the efficacy with lower dose regimens
11. First-line treatment of non-small cell lung cancer with docetaxel and cisplatin: A multicenter phase II study
12. Interim analysis of a phase II study of docetaxel (Taxotere) in combination with cisplatin in Korean patients with metastatic (stage IV) or unresected (stage IIIB) localized non-small cell lung cancer
13. First line treatment of advanced non-small cell lung cancer with docetaxel and cisplatin: A multicenter phase II study
14. Combination treatment with docetaxel (Taxotere) and platinum compounds for non-small cell lung cancer
15. Docetaxel plus cisplatin versus docetaxel plus gemcitabine chemotherapy in advanced non-small cell lung cancer: A preliminary analysis of a multicenter randomized phase II trial
16. Docetaxel (Taxotere) and cisplatin in metastatic urothelial cancer: A phase II study
17. Neo-adjuvant docetaxel and cisplatin for muscle-invasive carcinoma of the bladder
18. Phase II study of docetaxel (D) and cisplatin (CDDP) in advanced urothelial carcinoma: Preliminary results
19. A phase II study of docetaxel and cisplatin in patients with locally advanced, recurrent, and/or metastatic squamous cell carcinoma of head and neck (SCCHN), not curable by standard therapy
20. Phase II study of Taxotere and cisplatin in patients with recurrent or disseminated squamous cell head and neck cancer
21. Phase II study of docetaxel (D) and cisplatin (CDDP) in first line treatment of disseminated small cell lung cancer (SCLC): Preliminary results
22. Phase II study of docetaxel and cisplatin in a circadian timing as first line chemotherapy in advanced non small cell lung cancer
23. Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer
24. Phase I/II study of docetaxel and carboplatin as 1st line chemotherapy in advanced non-small cell lung cancer. Preliminary results
25. Use of docetaxel and carboplatin for patients with non-small cell lung cancer
26. Docetaxel (Taxotere) in combination with platinum-based regimens in non-small cell lung cancer: Results and future developments
27. Docetaxel (Taxotere) and carboplatin in the treatment of advanced non-small cell lung cancer
28. Multi-institutional phase II trial of docetaxel and carboplatin combination in patients with stage IIIB and IV non-small cell lung cancer
29. Outpatient Taxotere/carboplatin (T/C) combination therapy in NSCLC for induction in stage IIIB and palliation in stage IV
30. Phase II trial of docetaxel and carboplatin in advanced non-small cell lung cancer
31. Docetaxel/carboplatin combination therapy for stage IIIB/IV non-small cell lung cancer
32. Combination chemotherapy with carboplatin, docetaxel and gemcitabine in advanced non-small cell lung cancer: A phase II study
33. Neoadjuvant chemotherapy with docetaxel (Taxotere) and cisplatin in patients with non-small cell lung cancer, stage IIIA, N2 is highly active with few toxicities
34. Docetaxel and cisplatin as induction and concomitant chemotherapy combined with accelerated radiotherapy for stage III non-small cell lung cancer - A phase II study
35. A comparison of patterns of care of non-small cell lung carcinoma patients in a younger and Medigap commercially insured cohort